This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Nicholas Galakatos
Global Head of Life Sciences at Blackstone

Profile

Nicholas Galakatos is the Head of the Blackstone Life Sciences business, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception. Dr.Galakatos has over 30 years of industry and investment experience and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital,. From 1997 to 2000 he was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO Dr. Galakatos is the Chairman of Anthos Therapeutics and Praxis Precision Medicine, and a member of the Board of Directors of Entasis Therapeutics (NASDAQ: ETTX) and Talaris, Inc.


Agenda Sessions

  • Investing in innovation – Blackstone’s journey into Life Sciences

    14:30